Patents
Literature
Patsnap Eureka AI that helps you search prior art, draft patents, and assess FTO risks, powered by patent and scientific literature data.

287 results about "Polymyxin" patented technology

Polymyxins are antibiotics. Polymyxins B and E (also known as colistin) are used in the treatment of Gram-negative bacterial infections. They work mostly by breaking up the bacterial cell membrane. They are part of a broader class of molecules called nonribosomal peptides.

Mutant of polymyxin efflux transporter and application thereof

The invention belongs to the technical field of gene engineering, and particularly relates to a mutant of polymyxin efflux transporter and application of the mutant. The mutant is a PmxD transporter mutant, the amino acid sequence of the PmxD transporter mutant is shown as SEQ ID NO: 1, and compared with wild type PmxD, the polymyxin transport capacity of the PmxD transporter mutant (T38W) is improved by 450.46%; and the total discharge amount of polymyxin is increased by 85.72%. Meanwhile, the mutant can significantly improve the growth ability of the strain on a plate containing 250 [mu] g / mL of polymyxin B, namely significantly improve the autoresistance of paenibacillus polymyxa to polymyxin.
Owner:SHANDONG AGRICULTURAL UNIVERSITY

Application of combination of magnolol and polymyxin in preparation of salmonella infection resisting medicine

The invention belongs to the technical field of biological medicine, and discloses application of magnolol as a polymyxin synergist in inhibition of salmonella. The application finds that the combination of magnolol and polymyxin has a good synergistic effect on salmonella in vitro and in vivo experiments. Compared with the traditional method of killing salmonella through combination of antibiotics, the method has the advantages that the magnolol and the polymyxin which are plant-derived synergistically kill bacteria, the generation of bacterial drug resistance is not easy to induce, and the magnolol has the characteristics of wide source, low price and good treatment effect; the method has good research and application significance for excavating antibiotic synergistic substitution and solving bacterial drug resistance.
Owner:SOUTH CHINA AGRICULTURAL UNIVERSITY

Bimodal polymyxin drug resistance gene MCR-1 detection platform

The invention discloses a bimodal polymyxin drug-resistant gene MCR-1 detection platform, relates to the field of food safety and analytical chemistry, and in particular relates to an on-site rapid detection method of the polymyxin drug-resistant gene MCR-1 in a food sample, primer groups aiming at the polymyxin drug-resistant gene MCR-1 are respectively as shown in SEQ ID NO.1, SEQ ID NO.2, SEQ ID NO.3, SEQ ID NO.4 and SEQ ID NO.5, and a sixth primer with the 5'end labeled by biotin; the CRISPR / dCas9 system comprises dCas9 protein and sgRNA, and the sequence of the sgRNA is marked as SEQ ID NO.7; the sequence of the gold-platinum nanoprobe is marked as SEQ ID NO.8; the LAMP technology is adopted to amplify the polymyxin drug-resistant gene MCR-1 in the sample to be detected, an LAMP product contains multiple sections of reverse circulation repetitive sequences, and each double strand can be combined with more gold-platinum nanoparticles, so that sensitive detection of the food-borne pathogenic bacteria containing the polymyxin drug-resistant gene MCR-1 in the food sample is realized, the sensitivity is relatively high, the detection time is short, the detection time is short, and the cost is low. The operation is simple, the stability is high, and the whole detection process can be completed in a short time.
Owner:ANHUI MEDICAL UNIV

Application of NSC348884 in preparation of antibacterial drugs

The invention discloses an application of NSC348884 in preparation of an antibacterial drug, the bacteria of the NSC348884 are gram-negative bacteria or drug-resistant gram-negative bacteria, and the gram-negative bacteria are acinetobacter baumannii, escherichia coli, pseudomonas aeruginosa or klebsiella pneumoniae; based on an antibacterial drug high-throughput screening technology, it is found from 1280 small molecule compounds that the benzimidazole compound NSC348884 has direct bacteriostasis and sterilization effects on gram-negative bacteria and drug-resistant gram-negative bacteria, and no drug resistance is generated after the benzimidazole compound NSC348884 is continuously applied for 14 days. Further research shows that NSC348884 can interfere with lipid synthesis of gram-negative bacterium cell membranes, inhibit formation of biological membranes and induce lipid metabolism disorder, so that bacteriostatic and bactericidal effects are achieved. In addition, the NSC348884 can also enhance the sensitivity of the drug-resistant bacteria to the imipenem and the polymyxin B.
Owner:THE SECOND HOSPITAL OF DALIAN MEDICAL UNIV

Fluorene alcohol derivative and application thereof

The invention provides a fluorenyl alcohol derivative which can be used as an antibiotic adjuvant with a broad-spectrum synergistic effect. According to the compound, bacteria outer membrane asymmetric protein MlaC and phospholipase A1 PldA are taken as targets, and a series of fluorenyl alcohol derivatives targeting the bacteria outer membrane asymmetric protein MlaC and phospholipase A1 PldA are obtained through screening. The preferable compound WTU-15 can improve the antibacterial activity of antibiotics such as polymyxin, cefepime, tetracycline and the like on negative bacteria such as sensitive and drug-resistant escherichia coli, salmonella, klebsiella pneumoniae, acinetobacter baumannii and the like, and can also improve the in-vivo treatment effect of cefepime on mice infected by the drug-resistant acinetobacter baumannii. And the visceral organs of the mice survived after administration have fewer bacteria, and the mice are better after being healed. Normal physiological and visceral organ functions of the mouse are not affected by single and continuous administration of the WTU-15.
Owner:CHINA AGRI UNIV

Polymyxin B functionalized nanoprobe as well as preparation method and application thereof

The invention belongs to the technical field of nanoprobes, and particularly relates to a polymyxin B functionalized nanoprobe and a preparation method and application thereof.The nanoprobe comprises magnetic nanoparticles and long-afterglow nanoparticles, the surfaces of the magnetic nanoparticles and the long-afterglow nanoparticles are modified with polymyxin B respectively, and the polymyxin B functionalized nanoprobe is formed by modifying polymyxin B on the surfaces of the magnetic nanoparticles and the long-afterglow nanoparticles. The preparation method of the nanoprobe comprises a method for modifying long afterglow nanoparticles with polymyxin B and a method for modifying magnetic nanoparticles with polymyxin B. According to the nanoprobe disclosed by the invention, the magnetic nanoparticles with separation and enrichment effects and the long afterglow nanoparticles with afterglow luminescence and interference resistance are prepared on the basis of taking antibiotics as recognition molecules; through the enriched and separated magnetic nanoparticles and the long afterglow nanoparticles for providing signals, a new detection means is provided for rapid and quantitative background-free detection of gram-negative bacteria.
Owner:CHONGQING MEDICAL UNIVERSITY

Application of combination of valnemulin and polymyxin in preparation of bactericide

ActiveCN119113081Alow therapeutic doserestore antimicrobial activityAntibacterial agentsCyclic peptide ingredientsCytotoxicityAntibacterial activity
The invention discloses an application of combination of valnemulin and polymyxin in preparation of a bactericide. The valnemulin and the polymyxin cooperate to kill bacteria, the antibacterial activity of the polymyxin on gram-negative bacteria which are drug-resistant and sensitive to the polymyxin such as escherichia coli, klebsiella pneumoniae and acinetobacter pideri can be effectively recovered in vitro and in vivo, in addition, the valnemulin has no cytotoxicity to mammalian cells, and the antibacterial activity of the polymyxin on the gram-negative bacteria can be effectively recovered. The application of valnemulin effectively reduces the therapeutic dose of polymyxin, and reduces the side effect risk of polymyxin on mammals.
Owner:ZHEJIANG UNIV

Polymyxin inhalation liquid preparation and preparation method thereof

ActiveCN119523952Asimple compositionreduce spasmsPowder deliverySpray deliveryBronchospasmInhalation
The invention relates to a polymyxin inhalation liquid preparation and a preparation method thereof. The polymyxin inhalation liquid preparation comprises 0.1-5% (W / V) of polymyxin B sulfate, 0.05-1% (W / V) of a stabilizer, 0.1-0.9% (W / V) of an osmotic pressure regulator, a pH value regulator and a solvent, the pH (Potential of Hydrogen) of the liquid preparation is 3.0 to 6.0; the solvent is selected from purified water and water for injection; the polymyxin inhalation solution provided by the invention is simple in composition, the pH value of the polymyxin inhalation solution is 3.0-6.0, osmotic pressure and isotonic pressure are simultaneously realized, bronchus spasm and cough caused by the polymyxin inhalation solution can be reduced, safety evaluation verifies that the polymyxin inhalation solution has better safety, and a new choice is provided for clinical application.
Owner:THE FOURTH HOSPITAL OF HEBEI MEDICAL UNIVERSITY (HEBEI CANCER HOSPITAL) +1

Pharmaceutical composition, glycyrrhizic acid and polymyxin B self-assembled carrier-free hydrogel as well as preparation method and application of glycyrrhizic acid and polymyxin B self-assembled carrier-free hydrogel

The invention provides a pharmaceutical composition, glycyrrhizic acid and polymyxin B self-assembled carrier-free hydrogel as well as a preparation method and application thereof, and belongs to the technical field of biological medicines. The invention provides a pharmaceutical composition. The pharmaceutical composition comprises glycyrrhizic acid and polymyxin B. According to the pharmaceutical composition, the inhibition effect on MRSA is enhanced through drug combination, the use of polymyxin B is reduced through the synergistic effect, and the development pressure of antibiotic drug resistance is relieved. According to the hydrogel formed by crosslinking the glycyrrhizic acid and the calcium chloride, the glycyrrhizic acid and the calcium chloride are crosslinked to form the hydrogel, and the calcium chloride is introduced into a glycyrrhizic acid system to increase the mechanical strength of the glycyrrhizic acid hydrogel, so that the glycyrrhizic acid hydrogel can be better attached to a wound. The invention provides a glycyrrhizic acid and polymyxin B self-assembled carrier-free hydrogel and a preparation method of the glycyrrhizic acid and polymyxin B self-assembled carrier-free hydrogel. The hydrogel does not contain any inert carrier component at all, the drug loading rate of 100% is achieved, and adverse reactions possibly caused by a traditional carrier system are effectively avoided.
Owner:ANHUI AGRICULTURAL UNIVERSITY

Phage lyase and application thereof

The invention discloses a bacteriophage lyase and application thereof, and particularly relates to a bacteriophage lyase with an amino acid sequence as shown in SEQ INNO.2. The bacteriophage lyase can inhibit the growth of escherichia coli, staphylococcus and salmonella, can be used as an antibacterial substance in splitting gram-negative bacteria and can be used for preparing drugs for resisting gram-negative bacteria. The lyase can be used independently or compounded with other substances, the use concentration of antibiotics can be reduced by combining the lyase with the antibiotics, toxic and side effects (such as renal toxicity of polymyxin) of drugs are reduced, and meanwhile, generation of bacterial drug resistance is delayed. After the lyase and the chitosan are combined for use, remarkable antibacterial activity is generated, the antibacterial effect can be achieved without pre-treatment on bacteria, and the practicability is improved.
Owner:GUANGDONG MEDICAL UNIV

DsRNA capable of simultaneously preventing and treating various thrips and application of dsRNA

PendingCN121087038ABiocideAnimal repellantsBiotechnologyAdult stage
The invention relates to dsRNA capable of simultaneously preventing and treating various thrips and application of the dsRNA. Specifically, the invention provides a dsRNA construct, the construct of the dsRNA is a double strand, and the construct of the dsRNA comprises a nucleotide sequence of an insect nymph and / or adult stage regulation related gene or fragment; wherein the insect nymph and / or adult stage regulation related gene is an Actin gene, and the dsRNA is obtained by amplifying a sequence as shown in SEQ ID NO: 9-10. The fusion type dsRNA is designed to target a plurality of conservative thysanoptera actin gene dsRNA, so that the multi-killing effect is achieved, and the prevention and treatment effect of the fusion type dsRNA is equivalent to that of spinetoram which is commonly used in the market at present.
Owner:SHANGHAI JIAOTONG UNIV

Application of dronedarone hydrochloride as polymyxin synergist

The invention relates to application of dronedarone hydrochloride in preparation of a polymyxin synergist. A checkerboard method-minimum inhibitory concentration test, a growth curve test and a sterilization curve test prove that dronedarone hydrochloride and colistin have a good in-vitro synergistic antibacterial effect; an isothermal titration calorimetry test confirms that dronedarone hydrochloride can play a synergistic antibacterial role by combining cardiolipin and phosphatidyl glycerol. Meanwhile, a mouse ExPEC drug-resistant strain abdominal cavity infection model shows that the dronedarone hydrochloride can remarkably enhance the in-vivo treatment effect of the colistin. Compared with drug research and development of unknown active compounds, the dronedarone hydrochloride as a marketed drug can effectively accelerate the research and development process of new drugs and reduce the risk of drug research and development failure, which is of great significance in prolonging the antibacterial activity of existing antibiotics and solving the problem of bacterial drug resistance.
Owner:JILIN UNIVERSITY

Nanoprobe as well as preparation method and application thereof

The invention belongs to the technical field of nano-probes, and particularly relates to a nano-probe and a preparation method and application thereof.The nano-probe comprises a magnetic nano-material and a long afterglow nano-material, the magnetic nano-material comprises magnetic nano-particles modified with concanavalin A and is used for recognizing, capturing and separating bacteria, and the long afterglow nano-material is a long afterglow nano-material. The long-afterglow nano-material comprises green long-afterglow nano-particles of which the surfaces are modified with polymyxin B and red long-afterglow nano-particles of which the surfaces are modified with vancomycin, the green long-afterglow nanoparticles with the surfaces modified with polymyxin B and the red long-afterglow nanoparticles with the surfaces modified with vancomycin are respectively used for identifying anti-interference signal output, the nano-probe is applied to identification of gram-negative and positive bacteria, the anti-interference capability of detection can be improved, the whole process is rapid and simple, and the cost is low. And the cost is low, and the stability is high.
Owner:CHONGQING MEDICAL UNIVERSITY

Method for determining blood concentration of colistin E and detection product

The invention provides a method for determining the blood concentration of colistin E and a detection product, and relates to the technical field of polymyxin E detection. The method for determining the plasma concentration of the colistin E comprises the following steps: classifying the colistin E by molecular weight based on a liquid chromatography-mass spectrometry method, and deducting the content of sulfuric acid in the colistin E to obtain the plasma concentration of the colistin E. The detection accuracy of the polymyxin E is improved, the operation is simple, the universality is strong, and the method is suitable for measuring the content of the polymyxin E when colistin sulfate or CMS is clinically used.
Owner:GENERAL HOSPITAL OF PLA

Composition of thiazolidinyl urea compound and polymyxin and application of composition in preparation of salmonella infection resisting medicine

The invention belongs to the technical field of biological medicines, and discloses a composition of a thiazolidinyl urea compound and polymyxin and application of the composition to preparation of salmonella infection resisting medicines. According to a sterilization curve obtained after the thiazolidinyl urea compound and the polymyxin are combined for use, the 24-hour bacterium loading amount is reduced by more than 100 times compared with that of a single drug, and a good synergistic sterilization effect is shown when the thiazolidinyl urea compound and the polymyxin are combined for use. The thiazolidinyl urea compound is simple in source and synthesis, the dosage of polymyxin can be remarkably reduced, the possibility that the polymyxin generates drug resistance is reduced under the condition that a better sterilizing effect is achieved, and the thiazolidinyl urea compound has a better prospect in application of the polymyxin combined drug to the salmonella infection resisting drug.
Owner:SOUTH CHINA AGRICULTURAL UNIVERSITY

Application of cyclic peptide compound BIM 23042 or preparation of cyclic peptide compound BIM 23042 in preparation of medicine for treating bacterial infectious diseases

The invention discloses application of a cyclic peptide compound BIM 23042 or a preparation thereof in preparation of medicines for treating bacterial infectious diseases, and belongs to the technical field of medicines. The invention discloses a cyclic peptide compound BIM 23042 as an antibiotic synergist for the first time, and the cyclic peptide compound BIM 23042 is used for treating bacterial infectious diseases. According to the application disclosed by the invention, the cyclopeptide compound BIM 23042 and polymyxin are combined for use, so that the growth of gram-negative bacteria can be effectively and synergistically inhibited. The combined medication scheme shows a remarkable advantage in coping with acinetobacter baumannii. The cyclic peptide compound BIM 23042 disclosed by the invention has an anti-infection capability, and the anti-infection capability is specifically shown as reducing the inflammatory response of macrophage RAW 264.7 induced by LPS (Lipopolysaccharide) and also reducing the apoptosis of the macrophage RAW 264.7 caused by the LPS. The invention provides a new perspective for developing a novel drug-resistant gram-negative bacterium prevention and control strategy, and also provides a new treatment scheme for coping with bacterial infection.
Owner:YANGZHOU UNIV

Pseudomonas aeruginosa endotoxin specific binding polypeptide and application thereof

The invention belongs to the technical field of biology, and provides a pseudomonas aeruginosa endotoxin specific binding polypeptide and application thereof. The amino acid sequence of the polypeptide is shown as SEQ ID No. 1, SEQ ID No. 3 or SEQ ID No. 4 in a sequence table. Experiments prove that the polypeptide has excellent affinity with pseudomonas aeruginosa endotoxin, and compared with an existing anti-endotoxin clinical drug polymyxin B, the polypeptide has obviously better pseudomonas aeruginosa endotoxin detoxification capability. On the basis, the invention further provides application of the polypeptide in removal or separation or analysis of the endotoxin of the pseudomonas aeruginosa and application of the polypeptide in preparation of a detoxification medicine for the endotoxin of the pseudomonas aeruginosa. The polypeptide can be widely applied to the biomedical fields of biological separation, biological detection, disease diagnosis and treatment and the like.
Owner:DALIAN UNIV OF TECH

Multifunctional double-drug co-loaded nanoparticles as well as preparation method and application thereof

The invention discloses multifunctional double-drug co-loaded nanoparticles as well as a preparation method and application thereof, and belongs to the technical field of medicines. A Janus nano material composed of mesoporous silica and mesoporous polydopamine is respectively loaded with salvianolic acid B and polymyxin B under the condition of pH 4.5 to obtain the double-drug co-loaded nano-particles, the double-drug co-loaded nano-particles have good biocompatibility and synergistic treatment effect, and the double-drug co-loaded nano-particles can reduce active oxygen accumulation and inhibit oxidative stress and inflammatory response, so that the double-drug co-loaded nano-particles can be used for preparing the anti-inflammatory drug for treating the salvianolic acid B and the polymyxin B. The endothelial injury caused by sepsis is effectively relieved. The salvianolic acid B and the polymyxin B are loaded at the same time, the salvianolic acid B protects endothelial cells by removing active oxygen and reducing inflammatory reaction, the polymyxin B kills gram-negative bacteria by destroying bacterial cell membranes and reduces infection sources and endotoxin release, and through the synergistic effect of the salvianolic acid B and the polymyxin B, the blood vessel leakage can be reduced, and the blood vessel leakage can be reduced. And the integrity of the endothelial barrier can be enhanced, so that the aim of treating sepsis endothelial injury is fulfilled.
Owner:SOUTH CHINA UNIV OF TECH

Application of dehydrounionine in the preparation of drugs that reduce polymyxin toxicity

This invention provides the application of dehydrouncitonin in the preparation of drugs that reduce polymyxin toxicity, belonging to the field of pharmaceutical technology. This invention uses dehydrouncitonin in combination with polymyxin. The combined use of dehydrouncitonin and polymyxin E increased the viability of HEK293T and RAW264.7 cells to 87.7% and 94.3%, respectively, with highly significant differences compared to the control, indicating that treatment with dehydrouncitonin in combination with polymyxin E can significantly inhibit the cytotoxic effect of polymyxin E. This invention uses a mouse model to demonstrate that treatment with dehydrouncitonin in combination with polymyxin E can significantly reduce the neurotoxicity and nephrotoxicity of polymyxin E alone in mice, specifically manifested in improved neurobehavioral effects and improved histopathological effects on brain and kidney tissues. This invention uses dehydrouncitonin in combination with polymyxin E to significantly inhibit the cytotoxic, neurotoxic, and nephrotoxic effects of polymyxin E.
Owner:CHINA AGRI UNIV

Mesenchymal stem cell culture medium, preparation method and application thereof

The present application relates to the technical field of biology, and particularly relates to a mesenchymal stem cell culture medium and a preparation method and application thereof.The mesenchymal stem cell culture medium comprises a basic culture medium, fetal bovine serum, basic fibroblast growth factor, polymyxin B and deionized water.The present application can simultaneously improve the proliferation activity of mesenchymal stem cells and the secretion performance of HGF by simultaneously adding the basic fibroblast growth factor and the polymyxin B in the basic culture medium; more stem cells can be in the active proliferation and division process by limiting the content of the basic fibroblast growth factor in the mesenchymal stem cell culture medium to 5-50 ng / mL; and the secretion performance of HGF can be improved while the cell proliferation activity is maintained by limiting the content of the polymyxin B in the mesenchymal stem cell culture medium to 50-100 mu g / mL.
Owner:QIANSHI BIOTECHNOLOGY (SHANGHAI) CO LTD

Application of flufenamic acid in preparation of polymyxin E antibacterial synergist

PendingCN122056860AAntibacterial agentsOrganic active ingredientsFenamic acidFlufenamic acid
The invention relates to the technical field of biological medicine, in particular to application of flufenamic acid in preparation of a polymyxin E antibacterial synergist. The invention discloses an application of flufenamic acid in preparation of a polymyxin E antibacterial synergist, the flufenamic acid has no obvious antibacterial effect on salmonella when being independently used, but the flufenamic acid and polymyxin E can enhance the antibacterial activity of the polymyxin E on the salmonella and reduce the use dosage of the polymyxin E when being jointly used in and out of an animal body, so that the antibacterial effect of the polymyxin E on the salmonella can be enhanced. The antibacterial activity of the polymyxin E on salmonella is enhanced, and the drug resistance of the polymyxin E is inhibited. Flurfenamic acid is approved to be used for other purposes as FDA, and when the flurfenamic acid is combined with polymyxin E, the flurfenamic acid has the characteristic of high safety, and meanwhile, the generation of the drug resistance of the polymyxin E drugs can be effectively avoided. The invention provides a basis for mining a new antibacterial prevention and control strategy for the polymyxin E drug-resistant bacteria.
Owner:XINJIANG ACADEMY OF AGRI & RECLAMATION SCI +1

A polymyxin-resistant, extended-spectrum β-lactamase-producing Escherichia coli EC382-2-2 and its application

This invention discloses a polymyxin-resistant, extended-spectrum β-lactamase-producing *Escherichia coli* strain EC382-2-2 and its applications. The *E. coli* strain EC382-2-2 of this invention was deposited on October 27, 2022, at the Guangdong Provincial Microbial Culture Collection Center (GDMCC), located at 5th Floor, Building 59, No. 100 Xianlie Middle Road, Guangzhou, Guangdong Province, China, with accession number GDMCC No: 62929. *E. coli* EC382-2-2 simultaneously carries the *eae* virulence gene, the plasmid-mediated polymyxin resistance gene *mcr-1*, the extended-spectrum β-lactamase gene *CTX-M-55*, and other antibiotic resistance genes. *E. coli* EC382-2-2 carries 18 resistance genes and exhibits high-level resistance to multiple antibiotics, making it a promising model strain for screening novel antimicrobial drugs.
Owner:GUANGDONG INST OF MICROBIOLOGY GUANGDONG DETECTION CENT OF MICROBIOLOGY

Multifunctional polymyxin B nanoparticles as well as preparation and application thereof

The invention relates to the technical field of drugs, in particular to multifunctional polymyxin B nanoparticles and preparation and application thereof.The multifunctional nanospheres (HPK) of polymyxin B (PMB) are synthesized by connecting hyaluronic acid and polymyxin B through Schiff base bonds and combining KAFAK, and the multifunctional nanospheres (HPK) serve as candidate drugs for refractory infectious diseases and can release PMB in response to the infected microenvironment, so that the effect of treating the refractory infectious diseases is achieved. The targeted infection site removes bacteria and various inflammatory mediators to reduce cytokine storm, including removal of LPS and active oxygen, and inhibition of macrophage activation. Hyaluronic acid (HA) serves as a carrier of PMB, the HA and the PMB are tightly connected through a pH sensitive bond Schiff base bond, the hyaluronic acid can change the biological distribution condition of the PMB, and a targeted CD44 receptor, hyaluronidase and the Schiff base bond can achieve PMB acidic microenvironment targeted delivery and meanwhile cooperate with PMB to resist bacteria and KAFAK to resist inflammation. The design and preparation of HPK effectively achieve the effects of reducing toxicity and enhancing efficacy on PMB.
Owner:GUIZHOU MEDICAL UNIV

A strain of Lactobacillus acidophilus PKC6 and its application

The invention belongs to the field of microbial technology, and specifically relates to a strain of acid fish lactobacillus PKC6 and an application thereof. The acid fish lactobacillus PKC6 is deposited in the General Microbiological Center of the China Microbiological Culture Collection Administration Committee, and the deposit number is CGMCC NO. 27201. The new strain of acid fish lactobacillus PKC6 screened by the invention is resistant to gentamicin, polymyxin B, vancomycin, kanamycin and norfloxacin, sensitive to ampicillin, penicillin, cephalexin and doxycycline, and has a good inhibitory effect on Escherichia coli and Staphylococcus aureus; the strain screened by the invention, after being compounded with a composite enzyme and co-fermented with palm meal, can greatly increase the content of nutrients in the fermentation product, and has a more obvious promoting effect on the intestinal development of raised animals, thereby achieving the purpose of improving the palatability of feed and promoting intestinal development.
Owner:SHANDONG ACADEMY OF AGRICULTURAL SCIENCES

Beta-diketone amide compound and application thereof in preparation of gram bacterium infection resisting medicine

The invention provides a beta-diketoamide compound and application thereof in preparation of a gram infection resistant drug, the structural formula of the beta-diketoamide compound is as shown in formula (1), in the formula (1), R1 is H or halogen; r2 is nitro, alkyl, halogen or methoxyl. The beta-diketoamide compound disclosed by the invention comprises gram-positive bacteria such as staphylococcus aureus, enterococcus faecalis, enterococcus faecium and staphylococcus epidermidis and other clinical isolates, and shows antibacterial activity; after being combined with polymyxin, the compound has synergistic bacteriostatic activity on gram-negative bacteria such as acinetobacter baumannii, klebsiella pneumoniae, escherichia coli and pseudomonas aeruginosa, and can remove biofilms formed by staphylococcus aureus and enterococcus faecalis.
Owner:SHENZHEN NANSHAN DISTRICT PEOPLES HOSPITAL

Application of polymyxin B in weed control and use method

The invention discloses application of polymyxin B in control of various weeds, and belongs to the technical field of agricultural biology. On one hand, polymyxin B can effectively inhibit growth of roots of various weeds; on the other hand, the plant leaves can be whitened or withered by spraying the fertilizer on the leaves. Experiments show that the root growth inhibition effect of weeds such as arabidopsis thaliana and barnyard grass is enhanced along with increase of the concentration of the polymyxin B, when the concentration of the polymyxin B in a plant culture medium is 10 [mu] M, the arabidopsis thaliana has a stress phenomenon, and when the concentration of the polymyxin B is increased to 50 [mu] M, leaves of the arabidopsis thaliana have a whitening phenomenon and plants die. If a leaf spraying mode is adopted, spraying of polymyxin B with the concentration of 500 [mu] M can make barnyard grass leaves whitened, and alfalfa leaves can be damaged. And through experiments, polymyxin B can whiten various weeds such as ryegrass and amaranthus retroflexus, and the scheme has high efficiency and environmental friendliness.
Owner:GUIZHOU UNIV

Lipopeptide-containing fat dissolving product as well as preparation method and application thereof

The invention provides a lipopeptide-containing fat dissolving product as well as a preparation method and application thereof, and relates to the field of medical cosmetology. According to the invention, the lipopeptide is applied to the preparation of the fat-dissolving medicine for the first time, and the lipopeptide can be selected from one or more of surfactin, iturin, interleukin, abrumogen, daptomycin, polymyxin, bacitramycin L, phospholipid rhzomorph and bacitramycin D. According to the invention, the lipopeptide is directly injected into the subcutaneous adipose tissue for the first time, so that the accumulation of the local adipose tissue is reduced, and a new active ingredient is provided for the fat dissolving needle; the invention also proves that compared with sodium deoxycholate, the lipopeptide has higher fat-dissolving activity and lower effective dose when being used as a fat-dissolving component; lipopeptide is adopted as a new effective component of the fat-dissolving needle, so that the fat-dissolving needle is safer and more effective, the rupture of an injection part can be reduced, the fat-dissolving needle better fits the pH value of a human body, and the pain in the injection process is reduced.
Owner:BLOOMAGE BIOTECHNOLOGY CORP LTD

Compound leprosy treatment drug and preparation method and application thereof

This invention provides a compound drug for treating melioidosis, its preparation method, and its application. The drug comprises active components of traditional Chinese medicine, a bioactive preparation, and a pharmaceutically acceptable carrier. The active components of traditional Chinese medicine are primarily extracts of Scutellaria baicalensis, Coptis chinensis, Fagopyrum dibotrys, and Polygonum cuspidatum. The bioactive preparation includes polymyxin B, homoserine lactonease, and recombinant human β-defensin 3. The components work synergistically to construct a comprehensive intervention system covering all pathological stages, including biofilm disruption, sterilization, anti-endotoxin activity, intracellular bacterial clearance, immune regulation, and tissue repair. This system can effectively disrupt bacterial biofilms, kill multidrug-resistant strains, neutralize endotoxins, and eliminate latent intracellular bacteria, addressing the core pain points of existing melioidosis treatments, such as strong drug resistance, significant toxic side effects, and high recurrence rates. The preparation process of this invention is carried out under low-temperature and sterile conditions throughout, which fully preserves the stability of the active ingredients, making it suitable for industrial production. The drug can be prepared in various dosage forms, covering all clinical subtypes of melioidosis, and possesses clinical application value and promising prospects for widespread application.
Owner:HAIKOU THIRD PEOPLES HOSPITAL

Application of combination of ebbeselenium and polymyxin in preparation of salmonella infection resisting medicine

The invention belongs to the technical field of biological medicine, and discloses application of ebb-selenium as a polymyxin synergist in inhibition of salmonella. According to the application, the combination of ebb selenium and polymyxin has a good synergistic effect on salmonella in vitro and in vivo experiments. In a mouse salmonella infection model, compared with the bacterium carrying amount after single-drug treatment, the bacterium carrying amount in the animal liver after EBS and polymyxin combined treatment has the effect that the bacterium carrying amount in the animal liver is obviously reduced. The survival rate of animals treated by the combination of the EBS and the polymyxin is obviously increased compared with the survival rate of the animals treated by single medicines of the EBS and the polymyxin. Compared with the traditional method for killing salmonella through combination of antibiotics, the method has the advantages that the generation of bacterial drug resistance is not easily induced through the synergistic sterilization of the ebb-selenium and the polymyxin, and the ebb-selenium has the characteristics of wide source, multiple effects and good treatment effect, and has better research and application significance for excavating the synergistic replacement of the antibiotics and solving the bacterial drug resistance.
Owner:SOUTH CHINA AGRICULTURAL UNIVERSITY